MOUNTAIN VIEW, Calif.,
April 1, 2021 /PRNewswire/
-- Aditx Therapeutics, Inc. (Aditxt) (the "Company") (Nasdaq:
ADTX), a biotech innovation company focused on improving the health
of the immune system, today announced that Collection Sites, LLC
will offer AditxtScore™ for COVID-19 through its mobile testing
centers. Collection Sites, LLC is owned and operated by
Medivolve Inc. ("Medivolve") (NEO:MEDV; OTC:COPRF; FRA:4NC).
Collection Sites, LLC provides testing programs to various
organizations and customers in different industries, including
entertainment, travel, and education. As an AditxtScore™ Channel
Partner, Collection Sites, LLC will now offer its customers
AditxtScore™ for COVID-19 as an immune monitoring service.
Collection Sites, LLC can implement the test with current staff and
no additional investment. Specimens collected by Collection Sites
will be sent to, and processed at, Aditxt's CLIA-certified
AditxtScore™ Center.
"We welcome Collection Sites, LLC as an AditxtScore™ Channel
Partner and we look forward to working with their team to expand
the availability of AditxtScore™ for COVID-19 through their mobile
testing centers," said Amro Albanna,
co-Founder and CEO of Aditxt.
"As the rollout of COVID-19 vaccines progress across
the United States, people are
going to want to monitor their immunity levels regularly," added
Medivolve CEO, Doug Sommerville.
"This will be one of the many ongoing services offered through our
future telehealth sites as immune responsiveness will be top of
mind for people for the foreseeable future. We are excited to be
able to bring this testing modality to our customers and believe it
will be a significant revenue contributor over the coming now and
in the future."
For more information on AditxtScore™ and how it can bolster your
COVID-19 testing efforts, visit
www.aditxtscore.com
About Aditx Therapeutics
Aditxt is developing
technologies specifically focused on improving the health of the
immune system through immune monitoring and reprogramming. The
immune monitoring technology is designed to provide a personalized
comprehensive profile of the immune system. The immune
reprogramming technology is currently at the pre-clinical stage and
is designed to retrain the immune system to induce tolerance with
an objective of addressing rejection of transplanted organs,
autoimmune diseases, and allergies. For more information, please
visit: www.aditxt.com
About Medivolve Inc.
Medivolve Inc. (NEO:MEDV;
OTC:COPRF; FRA:4NC) seeks out disruptive technologies,
ground-breaking innovations, and exclusive partnerships to help
combat COVID-19 and generate remarkable risk-adjusted returns for
investors. Specifically, Medivolve offers investors a diversified
investment in the COVID-19 medical space across three areas;
prevention, detection, and treatment. Medivolve has a team of
renowned global medical and business advisors that have developed a
proprietary business strategy to capitalize on high-margin
opportunities in the COVID-19 space. Medivolve's primary
focus is to provide convenient and assessable medical services for
testing of the COVID-19 virus to help combat the pandemic. For more
information, please visit www.medivolve.ca.
Forward-Looking Statements
Certain statements in this
press release constitute "forward-looking statements" within the
meaning of the federal securities laws. Forward looking statements
include statements regarding the Company's intentions, beliefs,
projections, outlook, analyses or current expectations concerning,
among other things, the Company's ongoing and planned product
development; the Company's intellectual property position; the
Company's ability to develop commercial functions; expectations
regarding product launch and revenue; the Company's results of
operations, cash needs, spending, financial condition, liquidity,
prospects, growth and strategies; the industry in which the Company
operates; and the trends that may affect the industry or the
Company. Forward-looking statements are not guarantees of future
performance and actual results may differ materially from those
indicated by these forward-looking statements as a result of
various important factors, as well as those risks more fully
discussed in the section entitled "Risk Factors" in the Company's
most recent Annual Report on Form 10-K, as well as discussions of
potential risks, uncertainties, and other important factors in the
Company's subsequent filings with the Securities and Exchange
Commission. All such statements speak only as of the date made, and
the Company undertakes no obligation to update or revise publicly
any forward-looking statements, whether as a result of new
information, future events or otherwise.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/collection-sites-llc-named-aditxtscore-channel-partner-to-offer-aditxtscore-for-covid-19-immunity-status-monitoring-through-its-mobile-testing-centers-301260470.html
SOURCE Aditx Therapeutics, Inc.